Myriad International Management Team


Kerstin Bohmann

Director Regulatory Affairs

Kerstin joined the company with the acquisition of Sividon Diagnostics GmbH in June 2016 and assumed responsibility for Regulatory Affairs for the diagnostic kit business. As a cofounder and head of RA/QA of Sividon, she implemented and maintained an ISO 13485 certified QM system. In addition, she had the regulatory responsibility for CE marking the EndoPredict test as well as preparing a 510(k) submission to FDA for this test. She obtained a PhD in molecular biology and spent several years of academic research in renowned research institutes (EMBL in Heidelberg, Max-Planck-Institute for Developmental Biology in Tuebingen). Since 2000, she held different positions in research, development and project management in the diagnostic industry at Bayer Healthcare, Siemens and Sividon in Germany and the United States.


Franco Boretti

Country Manager Italy

Franco Boretti joined the company in January 2012. Mr. Boretti has more than 25 year of experience in the healthcare industry. He established marketing operations and served as General Manager in Italy at BRAHMS, a division of Thermo Fisher Scientific and prior to that at Quidel, where he was appointed General Manager for the South of Europe. He also worked for Chiron as Sales and Marketing Manager in Italy and for the pharmaceutical company Recordati as global Licensing Manager. Mr. Boretti holds a Master’s degree in Pharmaceutical Chemistry and Technology from the State University of Milan.


Paulo da Costa

Director, International Finance

During his professional life, Mr. Paulo da Costa had the opportunity to work in several sectors (banking, healthcare, pharmaceutical, biotechnology) and always in an international environment.
In 2002 Mr. da Costa started with KPMG where main activity was to provide recommendations to improve Bank’s investments portfolio. Late 2004 Mr. da Costa moved on to a SCA (Swedish Healthcare) where he learned the finance around healthcare products and distribution channels (both retail and B2B). Then in 2007 Mr. da Costa gathered healthcare international experience in Covidien where main goal was transfer processes to the Finance Shared Services sitting in Prague. In 2008 Mr. da Costa moved to Zurich to work with Baxter Healthcare in the Corporate Finance Department where main responsibility was to work together with the International Tax regarding the Transfer Price policies and support a lean, leveraged switch between management and statutory corporate view. In 2012, Mr. da Costa joined Myriad Genetics where he is responsible for all the international finance coordination.


Fani Kalaitsidis

Country Manager DACH (Germany, Austria and Switzerland)

Fani Kalaitsidis joined the company in January 2012 and has been appointed Country Manager DACH in July 2016. Fani has more than 16 years of healthcare experience and extensive knowledge in developing and implementing strategic plans to drive commercial growth in the life sciences, biotechnology, and diagnostic industries. Prior to joining Myriad, she held several positions at Baxter AG in the Bioscience care business. Fani is an accomplished senior executive experienced in positioning commercial companies for growth, profitability, and sustainable competitive advantage.
Fani received her Bachelor’s degree in Biology and Anthropology from Zurich University and her Executive Master’s degree of Business and Administration in General Management from St. Gallen University, Switzerland.


Gary A. King

Executive Vice President, International Operations

Gary A. King joined the company in July 2010. Mr. King has been employed in the life sciences industry for more than 25 years. Most recently he was the Chief Executive Officer of AverDx Incorporated, an international biotechnology company. Prior to AverDx, he was Vice President, International Operations at Biosite Incorporated where he spent six years building and leading all of the Company’s commercial activities outside the United States. He established marketing and logistics operations in Germany, France, Italy, the United Kingdom, Netherlands, and Belgium, and he established clinical operations and marketing programs in Asia. Prior to joining Biosite, Mr. King was Division Director in Japan for Guidant Corporation and led Guidant’s transition from distributor to direct operations in the Japanese market. Mr. King received his Bachelor of Arts degree in Zoology from Pomona College and a Masters of Business Administration degree from Stanford University.


Patrick Korman

Country Manager France

Patrick Korman joined Myriad Genetics in November 2011 as VP International, Business Development, Market Access and Public Affairs at Myriad Genetics in addition to CEO at Myriad Genetics France. He is now focusing on France as business and team are growing significantly since the first Myriad product is reimbursed in the country. Mr. Korman has been employed in the life sciences industry for 30 years. He served as CEO in a French biotech company, Fluigent, a spin-off of Curie Institute, and prior to that, he was CEO at Alexion Pharmaceutical France from the startup of the company and a Senior Member of Alexion Europe Leadership Team, spending 3 years establishing the business from MAA to pricing and first years of sales. Prior to Alexion, he built an extensive experience of the Pharma industry as VP in different international consulting firms. Mr. Korman has an MA Political Sciences and MBA from HEC.


Ralf Kronenwett

Director, International Medical Affairs

Ralf Kronenwett joined Myriad Genetics with the acquisition of Sividon Diagnostics in June 2016 and holds the position of Director Medical Affairs and Clinical Development Kits. He received his medical degree from the University of Heidelberg. After serving as a resident physician at the University Hospital Heidelberg, Ralf Kronenwett was a research group leader at the Clinical Cooperation Unit Molecular Hematology/Oncology of the German Cancer Research Centre in Heidelberg. In 1999, he moved to the University Hospital Dusseldorf, qualified as an Assistant Professor of Molecular Medicine and focused on molecular therapeutics and diagnostics in hematology/oncology as well as biology and therapeutic use of hematopoietic stem cells. From 2006 to 2010, he held positions as senior scientist at Bayer HealthCare and Siemens Healthcare Diagnostics and was working on prognostic and predictive biomarkers in breast cancer. In 2010, Ralf Kronenwett founded together with former colleagues at Siemens the company Sividon Diagnostics GmbH as a “management buyout” and held the positions of the Chief Medical Officer and Chief Scientific Officer (CMO/CSO). He was responsible for Medical Affairs, for R&D activities and for the development of the breast cancer prognosis test EndoPredict. Ralf Kronenwett was involved in several international research projects and is a coauthor of more than 90 research journal publications.


Lawrence Murphy

Director of International Sales

Lawrence Murphy joined Myriad Genetics in April 2012. Mr. Murphy has worked in the Commercial Life Sciences / Biotechnology sector for the last 18 years. Previous to his time with Myriad Genetics, Mr. Murphy worked in sales for several years at Life Technologies / Invitrogen in Australia before moving to the UK where he joined an Australian Biotechnology instrument Manufacturer €“ Corbett Research for nearly 9 years establishing their UK operations and building a team of Salespeople and Engineers. In another tenure within the same company he moved on to establishing the distributor networks for Corbett Research in Asia-Pacific where he focused mostly on China, South Korea, Japan & India and worked closely with them to develop sales across the region. Lawrence also spent several years based back in London with Illumina a Next Generation Sequencing & Microarray leader establishing their Distributor Network across Europe, Russia, The Middle East and South Africa. Mr. Murphy has also spent more than 5 years working in Laboratory Research as well working on a variety of projects from Asian Schistosomiasis Vaccine development to Environmental Toxicology to Plant AgriGenomics. Mr. Murphy gained a Bachelor of Applied Science majoring in Molecular Biology / Genetics at the Queensland University of Technology in Brisbane Australia.


Frank Nowas

Director Customer and Kits Operations

Frank Nowas has worked in various roles within the In-Vitro-Diagnostics and Life Science industry for 21 years. After many years in technical field service and product support functions with Beckman Coulter in Europe, he became European Project Manager for laboratory automation and led later on the Clinical Diagnostics Service Germany West. He then spent nearly five years with the German subsidiary of Waters Inc. as National Service Manager. There he managed Field Service, Customer Support and Customer training. Excellent customer service for clinical customers, pharmaceutical and chemistry industry, universities and public institutions have been the main focus of his work there. Most recently, Mr. Nowas served as Director Services International in the area of gastroenterology. His responsibilities contained optimization of customer service for direct customers and distributors throughout the world, continuous improvement to the repair center as well as creating technical support capabilities outside Europe.
Mr. Nowas received his diploma in Biomedical Engineering from the University of Applied Science in Aachen.


Heinz Oehl

Senior Director International Market Access & Integrated Patient Care

Heinz Oehl, MD has 15 years’ experience in healthcare and life science industry. As Senior Director Market Access and Integrated Patient Care, he aims to have more patients benefit from earlier and more broad adoption of personalized medicine through innovative in-vitro- and companion-diagnostic technologies. He and his team seek to speed up access for patients and care-givers to diagnostic advancements to transform standard of care towards individualized therapies.
He runs and oversees Myriad’s hospital and multidisciplinary ambulatory-care operations in Germany, a unique platform for partnering and for developing innovative molecular in-vitro diagnostics close to the patient.
Heinz Oehl joined Myriad in January 2012. In his previous position as Country Manager Germany and Austria, he established Myriad’s country organization and laid the foundation to offer direct-to-patient care and to partner with providers and payers within the healthcare system.
Before joining Myriad, he worked in various executive positions in the international Medical Device and Pharmaceutical industry. Previously, he drove transformation of markets in Europe, Middle East and Africa towards adoption of new life-saving organ replacement therapies in various disease entities and pathways.
Heinz Oehl carries a medical license from Free University of Berlin and was trained in Germany and the University of California in San Diego as well as at IMD executive business school in Lausanne, Switzerland.


Mona Prasad

Canadian Sales and Business Unit Manager

Mona Prasad joined the company in February 2015. Ms. Prasad has been in the Life Science industry for more than 12 years. Most recently she was at Agilent Technologies where she spent 8 years building and growing the genomics business in Canada, in both the clinical and research markets. Prior to this, she was at the Ontario Cancer Institute and University Health Network where she was involved in ovarian and breast cancer research. Ms. Prasad earned her Bachelors of Science and Masters of Science degree in Molecular Biology and Biotechnology from McMaster University and a Masters of Business Administration degree from Wilfrid Laurier University.

Jan Schlüchter

Jan Schlüchter

Managing Director Europe – Chief Commercial Officer

Jan Schlüchter joined the company in October 2015. As Managing Director Europe and Chief Commercial Officer, he oversees Country Operations across Europe. Jan has held several senior positions at Novartis over the past 12 years. Most recently, he served as Global Head of Key Account Management at Novartis’ headquarters in Basel, Switzerland. Previously, he held General Management roles in Greece and Germany.
Before Novartis, Jan was a Consultant at McKinsey and has founded two companies. He received his master’s degree in management from the University of Nuremberg, Germany and his doctor of philosophy degree in marketing from the University of Dortmund, Germany.


David Spackman

Country Manager UK and Ireland

David’s scientific career began in drug discovery following a PhD and Post-doctoral research in synthetic organic chemistry. After some years as a medicinal chemist, David moved into a more commercial role before joining Fisher Scientific UK Ltd as a sales representative. Following an MBA at Imperial College, London focused on healthcare, David Joined MeadWestvaco a world leading packaging manufacturer in business development progressing to European Sales Director for the Adherence Packaging and Pump Dispenser business. A second spell at Thermo Fisher Scientific saw David managing the UK, Ireland and Netherlands Clinical Diagnostics business, bringing together the innovative biomarker business with the well-established Drugs of Abuse and quality controls portfolio. David brings a good deal of experience in UK market access, having worked closely with NICE, the NIHR Diagnostic Evidence Cooperatives and NHS England. He has expertise in Health Economics, Decision Impact modelling and guideline processes.


Saskia Wehnelt

Senior Director of Development and Operations

Saskia Wehnelt joined the company in July 2011. Ms. Wehnelt has over 16-years of laboratory experience. Currently, Ms. Wehnelt is leading the international laboratory in Martinsried, Germany which is developing, validating and performing analytical tests. This includes establishing the lab in concordance with regional and international laws and standards, coordinating customer needs worldwide, implementing Kaizen principles and creating and maintaining standards that match the high quality of results generated at Myriad Genetics, Inc. Prior to joining Myriad Ms. Wehnelt was the Technical Project Manager of Eurofins Medigenomix GmbH, an innovative European bioanalytical company. In this position she was responsible for laboratory organization, introduced internal structures and led the process for automation of analytical processes. She also served as the study director for clinical studies and was a member of the quality management group of the company. She has experience in exon sequencing, de novo gene synthesis, cloning and pharmacogenetic testing from her role as Deputy Unit Manager of the Molecular Biological Applications Group. As a successful group leader she was also responsible for development, customer contacts and training plans. Ms. Wehnelt received her Diploma in Biology from the Ludwig Maximilians University in Munich.